Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)

Q: What does CUSIP 98943L107 represent in this 13F holders report?

CUSIP 98943L107 is the security identifier for ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in Q4 2025?

85 institutional investors reported ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 98943L107

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock,$0.001 par value per share
Shares outstanding: 72,096,078
Total 13F shares: 40,517,312
Share change: -12,771,099
Total reported value: $54,747,323
Price per share: $1.35
Number of holders: 85
Value change: -$19,981,164
Number of buys: 32
Number of sells: 46

Quarterly Holders Quick Answers

What is CUSIP 98943L107?
CUSIP 98943L107 identifies ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 98943L107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Anthony Y. Sun	3/4/5	President & CEO, Director	— class O/S missing	2,592,141	$26,672,095	—	04 Apr 2022	3/4/5
Matrix Capital Management Company, LP	13F 3/4/5	Company · 10%+ Owner	9% from 3/4/5	13,959,973	$21,079,559	—	30 Sep 2025	13F 3/4/5
WALTERS GROUP	13D/G 3/4/5	Walters William T · 10%+ Owner	20%	13,509,973	$20,264,960	$0	31 Dec 2025	13D/G 3/4/5
Iris Roth	3/4/5	Chief Operating Officer	— mixed-class rows	350,000 mixed-class rows	$14,760,704	—	01 Mar 2023	3/4/5
Walters William T.	13D/G	—	9.9%	7,050,000	$10,081,500	+$786,500	29 Jan 2025	13D/G
Kevin D. Bunker	3/4/5	Chief Scientific Officer	— class O/S missing	850,281	$8,749,051	—	20 Dec 2023	3/4/5
Cam Gallagher	3/4/5	President, Interim CFO, Director	— mixed-class rows	826,180 mixed-class rows	$7,591,486	—	31 May 2024	3/4/5
5AM Opportunities II (GP), LLC	13D/G	Andrew J. Schwab	6.4%	4,838,571	$7,257,856	$0	18 Dec 2025	13D/G
BARCLAYS PLC	13D/G 13F	Company	5.3%	3,841,449	$5,800,588	$0	30 Sep 2025	13D/G 13F
Kimberly Blackwell	3/4/5	Chief Executive Officer, Director	— mixed-class rows	734,145 mixed-class rows	$5,659,655	—	01 Feb 2024	3/4/5
Melissa B. Epperly	3/4/5	Chief Financial Officer	— mixed-class rows	526,449 mixed-class rows	$5,164,577	—	12 Feb 2024	3/4/5
Diana F. Hausman	3/4/5	Chief Medical Officer	— mixed-class rows	711,376 mixed-class rows	$4,718,315	—	09 May 2024	3/4/5
VANGUARD GROUP INC	13D/G 13F	The Vanguard Group · Company	4.6%	3,271,240	$4,677,873	$0	31 Dec 2024	13D/G 13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	3.9%	2,845,152	$4,291,000	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	3.2%	2,325,355	$3,511,286	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	2.9%	2,077,290	$3,136,708	—	30 Sep 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	2.1%	1,550,000	$2,340,500	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	2.1%	1,548,781	$2,338,660	—	30 Sep 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	2%	1,461,200	$2,206,412	—	30 Sep 2025	13F
D. E. Shaw & Co., Inc.	13F	Company	2%	1,408,803	$2,127,292	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	2%	1,407,829	$2,125,823	—	30 Sep 2025	13F
Alexis Pinto	3/4/5	Chief Legal Officer	— mixed-class rows	60,729 mixed-class rows	$2,068,615	—	10 Feb 2022	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	1.9%	1,363,347	$2,058,654	—	30 Sep 2025	13F
Decheng Capital LLC	13F	Company	1.8%	1,323,327	$1,998,224	—	30 Sep 2025	13F
BlackRock, Inc.	13D/G 13F	Company	2.2%	1,613,323	$1,952,121	$0	30 Jun 2025	13D/G 13F
Andrea Paul	3/4/5	Chief Legal Officer	— mixed-class rows	1,195,498 mixed-class rows	$1,832,647	—	03 Feb 2025	3/4/5
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	1.6%	1,185,521	$1,790,137	—	30 Sep 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	1.5%	1,077,656	$1,627,000	—	30 Sep 2025	13F
PRIMECAP MANAGEMENT CO/CA/	13F	Company	1.3%	962,620	$1,453,556	—	30 Sep 2025	13F
TYBOURNE CAPITAL MANAGEMENT (HK) LTD	13F	Company	1.3%	961,486	$1,451,844	—	30 Sep 2025	13F
PFIZER INC	13F	Company	1.3%	953,834	$1,440,289	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F 13D/G	Company	1.3% from 13D/G	902,521	$1,362,807	—	30 Sep 2025	13F 13D/G
Dimitris Voliotis	3/4/5	SVP, Clinical Development	— mixed-class rows	40,212 mixed-class rows	$1,322,792	—	10 Feb 2022	3/4/5
JPMORGAN CHASE & CO	13F	Company	1%	723,075	$1,091,843	—	30 Sep 2025	13F
Carrie Brownstein	3/4/5	Chief Medical Officer	— class O/S missing	105,685	$1,087,456	—	04 Oct 2023	3/4/5
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.97%	700,576	$1,057,870	—	30 Sep 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.9%	645,623	$974,891	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.82%	589,222	$890,229	—	30 Sep 2025	13F
Mark Lackner	3/4/5	Chief Scientific Officer	— mixed-class rows	637,570 mixed-class rows	$877,753	—	03 Feb 2025	3/4/5
Peapod Lane Capital LLC	13F	Company	0.78%	565,371	$853,879	—	30 Sep 2025	13F
XTX Topco Ltd	13F	Company	0.76%	548,629	$828,430	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0.74%	532,678	$804,344	—	30 Sep 2025	13F
Woodline Partners LP	13F	Company	0.74%	530,582	$801,179	—	30 Sep 2025	13F
5AM Venture Management, LLC	13F	Company	0.68%	490,000	$739,900	—	30 Sep 2025	13F
Almitas Capital LLC	13F	Company	0.63%	457,322	$690,556	—	30 Sep 2025	13F
Stonepine Capital Management, LLC	13F	Company	0.63%	453,800	$685,238	—	30 Sep 2025	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.53%	380,822	$575,041	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.48%	345,155	$521,184	—	30 Sep 2025	13F
Opaleye Management Inc.	13F	Company	0.44%	316,550	$477,991	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	0.38%	271,790	$410,403	—	30 Sep 2025	13F

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q4 2025

As of 31 Dec 2025, Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by 85 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 40,517,312 shares. The largest 10 holders included 5AM Venture Management, LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., TWO SIGMA ADVISERS, LP, TWO SIGMA INVESTMENTS, LP, Opaleye Management Inc., and BANK OF AMERICA CORP /DE/. This page lists 85 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

-11

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.